XIAOMI-W(01810.HK) will spend HKD 151.33 million to repurchase 4 million shares on Jan 9, 2026 .
GEELY AUTO(00175.HK) will spend HKD 26.62 million to repurchase 1.55 million shares on Jan 9, 2026 .
Yue Da Commercial Factoring, a subsidiary of YUE DA INTL， has signed a new reverse factoring agreement with Binhai Chijin, providing a RMB43 million reverse revolving credit limit with an annual comprehensive return rate of 8.2% and a one-year term. When combined with similar related transactions in the past 12 months, this agreement constitutes a major transaction of the company.
By the close of trading on Jan 8, 2026, ILUVATAR COREX(09903.HK) saw a gain of 8.44% in its share price, closing at HKD 156.8. During the session, it reached an intraday high of HKD 192 and touched an intraday low of HKD 148.9.
JINKE SERVICES announced that CITIC Securities International Capital Management Limited lent 30,800 ordinary shares of the company on January 7. After the transaction, the company held 35,060,100 ordinary shares of Jinke Smart Services, accounting for 5.8718% of such securities.
CLOUDBREAK PHARMA INC. (02592.HK) announced that its indirectly wholly-owned subsidiary, Cloudbreak Biopharma Technology (Guangzhou) Co., Ltd., has received a court notice stating that due to an ongoing arbitration proceeding, approximately RMB 2.55 million in cash in its bank account has been subject to judicial preservation until November 30, 2026. The arbitration involves a claim for unpaid service fees of around US$2.05 million plus related interest.
GRAND MING announced that the exclusive period for the previous potential sale has expired without reaching a formal agreement. Meanwhile, the company stated that its subsidiary has entered into an exclusive rights agreement and letter of intent with a new potential buyer regarding the proposed acquisition of two properties in the New Territories, Hong Kong.
Air China (00753) announced that its wholly-owned subsidiary Easerich will place 108.08 million Cathay Pacific shares (approximately 1.61% of issued shares) with Morgan Stanley at HK$12.22 per share, expecting to realize a pre-tax profit of about RMB182 million. Post-transaction, Air China's stake will decrease to 27.11%, maintaining its position as an important strategic shareholder. The placement does not constitute a notifiable or connected transaction under Hong Kong Listing Rules and includes a 180-day lock-up period.
The Hong Kong stock market delivered strong performance in 2025, with the Hang Seng Index advancing 27.77% for the year—its best showing in five years. Among the top-performing constituents, China Hongqiao and Zijin Mining capitalized on rising metal prices to achieve substantial earnings growth, while SMIC benefited from the semiconductor sector recovery, posting 18.20% year-on-year revenue growth in the first three quarters. Conversely, Meituan saw profits tumble amid intensified industry competition, and Li Auto swung from profitability to losses. Institutional analysts believe that with continued policy support and capital inflows, the Hong Kong market is well-positioned to sustain its upward momentum in 2026.
S.F. Holding announced that as of December 31, 2025, it had repurchased a total of nearly 39 million A-shares with an aggregate amount of approximately RMB1.542 billion, representing 102.8% of the minimum target (RMB1.5 billion) under the share repurchase program, at an average transaction price of RMB39.59 per share.
EACON Group recently filed another listing application with the Hong Kong Stock Exchange, with Guotai Haitong Securities as the sole sponsor. According to Frost & Sullivan, the company is China's largest provider of autonomous driving solutions for mining areas by number of active mining trucks and 2024 revenue. The prospectus shows 2024 revenue of RMB 986 million and a three-year compound annual growth rate of 305.8%, though net losses continued to widen during the reporting period.
OneRobotics (stock code: 06600.HK) was listed on the Hong Kong Exchanges and Clearing Limited (HKEX) on December 30. On the following day, its shares closed 9.21% higher at HK$80.65, with a market capitalization of nearly HK$18 billion, earning it the title of "the first AI Embodied Home Robot Stock". Founded in Shenzhen in 2015, the company is headquartered in the city and houses its global sales and intelligent computing hubs in Hong Kong, focusing on the R&D of AI home robots. It has secured strategic investment from the Hong Kong Investment Corporation Limited (HKIC) as well as early backing from renowned semiconductor experts Li Zexiang and Gao Bingqiang.
Frontera Therapeutics recently submitted a listing application to the Hong Kong Stock Exchange (HKEX), with UBS Group and Guotai Haitong serving as joint sponsors. As a clinical-stage gene therapy company focused on recombinant adeno-associated virus (rAAV) gene therapies, it is the Chinese company with the most Investigational New Drug (IND) approvals for rAAV gene therapies, according to Frost & Sullivan. Its core products FT-002 and FT-003 have entered Phase II clinical trials. The prospectus shows the company has not yet generated revenue and has sustained losses during the reporting period.
In December 2025, the Hong Kong market welcomed at least 19 newly listed companies bearing the prestigious "First Stock" title in their respective fields. These enterprises are no longer limited to traditional giants but are widely distributed across high-growth sectors such as the digital economy (AI, Industrial Internet, Digital Assets), frontier technology (Silicon Carbide, Autonomous Driving, AI Drug Discovery), new consumption (Catering, Skincare), and other niche ind
